Two Sigma Advisers’s GoodRx Holdings GDRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-91,943
Closed -$249K 850
2025
Q4
$249K Sell
91,943
-429,657
-82% -$1.41M ﹤0.01% 2040
2025
Q3
$2.21M Sell
521,600
-294,400
-36% -$1.29M ﹤0.01% 1108
2025
Q2
$4.06M Buy
816,000
+125,000
+18% +$543K 0.01% 809
2025
Q1
$3.05M Sell
691,000
-63,000
-8% -$296K 0.01% 991
2024
Q4
$3.51M Buy
754,000
+308,000
+69% +$1.69M 0.01% 861
2024
Q3
$3.1M Sell
446,000
-291,800
-40% -$2.29M 0.01% 883
2024
Q2
$5.75M Sell
737,800
-173,900
-19% -$1.29M 0.01% 707
2024
Q1
$6.47M Buy
911,700
+68,300
+8% +$452K 0.02% 676
2023
Q4
$5.65M Sell
843,400
-94,200
-10% -$530K 0.01% 750
2023
Q3
$5.28M Sell
937,600
-119,500
-11% -$797K 0.01% 703
2023
Q2
$5.84M Sell
1,057,100
-318,300
-23% -$1.71M 0.01% 699
2023
Q1
$8.6M Buy
1,375,400
+136,700
+11% +$762K 0.02% 599
2022
Q4
$5.77M Sell
1,238,700
-139,000
-10% -$685K 0.02% 730
2022
Q3
$6.43M Sell
1,377,700
-57,600
-4% -$363K 0.02% 640
2022
Q2
$8.5M Buy
1,435,300
+1,134,700
+377% +$12.6M 0.02% 555
2022
Q1
$5.81M Buy
300,600
+293,800
+4,321% +$6.74M 0.02% 740
2021
Q4
$222K Buy
+6,800
New +$274K ﹤0.01% 2249

Other funds holding GDRX

Two Sigma Advisers's GDRX Position: Q1 2026 in Review

Two Sigma Advisers sold out of GoodRx Holdings (GDRX) in Q1 2026, closing a stake of 91,943 shares — an estimated $249K sold.

Two Sigma Advisers first reported a position in GDRX in Q4 2021 and held it in 17 quarters. The position peaked at $8.6M in Q1 2023. 174 funds tracked by Wall St. Rank hold GDRX as of Q1 2026.

  • Two Sigma Advisers reported no remaining GoodRx Holdings position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 91,943 GoodRx Holdings shares in Q1 2026, an estimated $249K.
  • Two Sigma Advisers first reported a position in GoodRx Holdings in Q4 2021 and held it in 17 quarters.
  • Two Sigma Advisers's GoodRx Holdings position peaked at $8.6M in Q1 2023.
  • 174 funds tracked by Wall St. Rank held GoodRx Holdings as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.